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Expression of tumour-suppressor gene Rb, apoptosis-suppressing protein
Bcl-2 and c-Myc have no independent prognostic value in renal
adenocarcinoma
P Lipponen', M Eskelinen2 and K Syrjiinen'
Departments of'Pathology and 2Surgery, University ofKuopio, FIN-70211 Kuopio, Finland.
Summary The expression of retinoblastoma (Rb), c-Myc and Bcl-2 proteins was studied by immunohisto-
chemical methods in 104 cases of renal adenocarcinoma. One tumour was completely negative for Rb protein
and altered expression pattern was detected in 36% of cases. A low fraction of Rb-positive nuclei was related
to high grade (P = 0.016) and high mitotic index (P = 0.012). Twenty-eight per cent of the tumours expressed
c-Myc in cancer cell nuclei and 87% showed cytoplasmic positivity. Cytoplasmic expression of c-Myc was
related to high grade (P= 0.002), while nuclear expression of c-Myc was related to small tumour diameter
(P = 0.034), low T category (P = 0.04), low mitotic index (P = 0.019) and expression ofc-ErbB-2 (P = 0.0007).
Overexpression of c-myc predicted favourable outcome in MO tumours (P = 0.0157). Bcl-2 was expressed in
20% of tumours and it was related to small tumour size (P<0.0001), low T category (P<0.0001), lack of
venous invasion (P= 0.008), node negativity (P = 0.015) and absence ofmetastasis (P = 0.017). In multivariate
analysis the expression of Rb, Bcl-2 and c-Myc had no independent prognostic value over T category
(P<0.001), mitotic index (P = 0.008) and combined nuclear grade (P = 0.056).
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The prognosis of renal adenocarcinoma depends on the
primary tumour size, histological features and proliferation
rate of tumour cells (Syrjanen and Hjelt, 1978a; Kinouchi et
al., 1989; Di Silvero et al., 1992; Eskelinen et al., 1993;
Lipponen et al., 1994). Recent results show that mutations
rarely occur in the c-erbB-2 and p53 genes in renal adenocar-
cinoma (Tal et al., 1988; Ogawa et al., 1992; Makos et al.,
1993; Lipponen et al., 1994) and they probably have no
independent prognostic value (Lipponen et al., 1994). Muta-
tions in tumour-suppressor genes p53 and Rb are common in
several types of neoplasms, and they also relate to prognosis
(Cordon-Cardo et al., 1992; Silvestrini et al., 1993). The
prognostic significance of Rb gene mutations is mainly un-
explored in renal adenocarcinoma (Ishikawa et al., 1991); the
results concerning Rb expression in other neoplasms suggest
that mutations in the Rb gene have prognostic significance
(Cordon-Cardo et al., 1992). The growth rate of neoplasms
depends on the proliferation and death rates of cancer cells,
which in part may represent programmed cell death or apop-
tosis (Allan et al., 1992; Sachs and Lotem, 1993). Mutations
in the bcl-2 gene inhibit apoptosis (Sachs and Lotem, 1993;
Schena et al., 1993) which may contribute to the develop-
ment of tumours and modify their clinical behaviour (Allan
et al., 1992; Sachs and Lotem, 1993; Schena et al., 1993).
Alterations in the c-myc gene family also regulate cell pro-
liferation and apoptosis (Evan and Littlewood, 1993; Kos-
kinen and Alitalo, 1993; Sachs and Lotem, 1993). Accord-
ingly bc1-2 and c-myc genes are in a central position in
regulating the direction of the cell cycle towards apoptosis or
mitosis. The present study was designed to analyse the prog-
nostic role of c-myc, bcl-2 and Rb gene expression by immuno-
histochemical methods in renal adenocarcinoma. This com-
bination of genes was selected because these genes play an
important role in regulating the growth rate of tumours.
Patients and methods
Patients, treatment andfollow-up
This study is based on a series of 135 patients operated on
for renal adenocarcinoma between 1968 and 1991 at the
Correspondence: P Lipponen, Department of Pathology, University
of Kuopio, POB 1627, FIN-70211 Kuopio, Finland
Received 5 August 1994; revised 15 December 1994; accepted 15
December 1994
Department of Surgery, Kuopio University Hospital (Eske-
linen et al., 1993; Lipponen et al., 1994). Paraffin-embedded
biopsies from the primary tumours in 104 cases were suitable
for immunohistochemical analysis. The staging of tumours
was done according to the International Union against
Cancer (UICC) standards (1987), based on routine imaging
methods and laboratory tests. The other pertinent clinical
data and the type of therapy are shown in Table I.
Histological grading of tumours was completed using the
nuclear grading system (three grades) (Syrjanen and Hjelt,
1978a) as well as the combined nuclear grading (six grades),
as detailed previously (Syrjanen and Hjelt, 1978b). The
mitotic figures were counted as described before, and the
mototic frequency per mm2 of the neoplastic epithelium was
used in the final analysis (Eskelinen et al., 1993).
Rb, Bcl-2 and c-Myc immunohistochemistry
Monoclonal anti-Rb protein (Novocastra Laboratories, New-
castle upon Tyne, UK) antibody (NCL-RB1) diluted at 1:40
was used to detect Rb protein expression. Monoclonal anti-c-
Myc protein (Novocastra Laboratories) antibody (NCL-
cMYC) diluted at 1:250 was used to detect c-Myc protein.
Polyclonal anti-Bcl-2 protein (Pharmingen, San Diego, Ca,
USA, cat. no. 14371E) antibody diluted at 1:400 was used in
detecting Bcl-2 protein. Sections (5gm) from the primary
tumours were used in all experiments and the staining
method has been described in detail previously (Lipponen et
al., 1994). However, the routine method was modified when
Rb and Bcl-2 proteins were detected. To detect Rb protein,
the sections were pretreated with 0.5% pepsin in 0.1%
Table I The clinical data of patients
Number of patients 104
Female/male 51/53
Mean (s.e.) (range) age at diagnosis 60.4 (1.0) (21.7-82.6) years
Follow-up, mean (s.e.) (range) 9.6 (0.3) (5.4-20.2)
Location right/left 58/46
Mean diameter (cm) (s.e.) (range) 6.9 (0.5) (2-23)
Therapy
Radical nephrectomy 101
Partial nephrectomy 1
Explorative laparotomy 2
Metastasis at diagnosis 26
Died of renal adenocarcinoma/other 63/3Rb, Bcd-2 and Myc proteins in renal adenocardnoma
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hydrochloric acid for 60 min at 37°C. For immunohisto-
chemical demonstration of Bcl-2 protein, the sections were
heated in a microwave oven for 2 x 5 min in 0.1 M citrate
buffer (pH 6.0) before incubation with the primary anti-
body.
Scoring ofstaining results
The fraction of nuclei (%) positive for Rb protein was
obtained by averaging the estimated fraction of positive
cancer cell nuclei in ten random fields (magnification 40 x,
field diameter 490ltm). As a second parameter, tumours with
a uniform, homogeneous nuclear staining pattern similar to
that of positive controls (normal urothelium), were scored as
having normal Rb expression (2) (Figure la) and completely
Rb negative tumours were scored as 0. Tumours with hetero-
geneous abnormal nuclear expression of Rb protein were
scored as 1 (Figure Ib). In these tumours Rb protein was
expressed as granular positivity not covering the entire
nuclear surface and the staining intensity was clearly weaker
than in tumours that expressed Rb protein normally.
The fraction of nuclei positive for c-Myc was scored using
the same method as in the scoring of the expression of Rb
protein and the cytoplasmic staining for c-Myc was scored
into four categories. Tumours with a strong homogeneous
cytoplasmic staining were scored as strong expression (3)
(Figure 1c) and completely negative tumours were scored as
0. Tumours with just identifiable weak expression of c-Myc
were scored as 1 and the tumours with a moderate expression
as 2. The expression of Bcl-2 (nucleus and cytoplasm) was
scored as negative or positive. As a second parameter the
fraction of nuclei positive for Bcl-2 protein (Figure Id) was
scored in a representative tumour area as for expression of
Rb protein.
b d
Figure 1 (a) Expression of Rb protein in renal adenocarcinoma. In this tumour expression was normal (score 2) (magnification
200 x). (b) A renal adenocarcinoma showing abnormal nuclear expression (score 1) of Rb protein (magnification 200 x). (c) A
renal adenocarcinoma with strong cytoplasmic expression ofc-Myc (magnification 200 x). A high fraction of Bcl-2 protein-positive
nuclei in a well-differentiated renal adenocarcinoma (magnification 200 x).
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oftp53 and c-ErbB-2 immunohistochemistry
These oncoproteins were detected as described previously
(Lipponen et al., 1994). In detecting p53 protein, polyclonal
rabbit anti-human p53 antibody CM 1 (Novocastra Labora-
tories) at a dilution of 1:1200 was used. To detect c-ErbB-2
oncoprotein, the slides were treated with 0.5% pepsin in
0.01 N hydrochloric acid for 60 min before adding the block-
ing normal horse serum. The monoclonal mouse anti-human
c-ErbB-2 antibody (NCL-1) (Triton Biosciences, Alameda,
CA, USA) diluted to 1:30 was used in detecting c-ErbB-2
protein.
Statistical methods
The statistical calculations were done by using the SPSS-X
program; the statistical tests used are indicated in the results
when appropriate. The univariate survival analysis (log-rank
analysis, SPSS-X) was based on the life table method with
the statistics of Lee and Desu (1972). Multivariate survival
analysis was done with the BMDP (2L) package (Cox, 1972)
in a stepwise manner, and only deaths due to renal cancer
were used as events. Multivariate analysis included only cases
for which a complete set of data was available. The year of
treatment, patient age and sex were included in the analysis
to control for their possible confounding effects.
Table II The mean (s.e.) of Rb-positive nuclei in various
subcategories of renal cell carcinoma
Positive nuclei for Rb
Variable n (s.e.) (%) Statistics
NGI 21 96.6 (1.4)
NG2 50 86.6 (3.2) F= 3.5, P = 0.031
NG3 33 80.9 (4.2)
CNG IA 11 96.3 (2.1)
CNG lB 11 97.1 (1.9)
CNG 2A 22 93.5 (2.0) F=2.9, P=0.016
CNG 2B 27 80.5 (2.1)
CNG 3A 8 71.8 (11.8)
CNG 3B 25 83.8 (4.0)
M/V index<7 70 91.1 (2.1) t=2.6, P=0.012
M/V index>7 34 78.1 (4.4)
NG, nuclear grade; CNG, combined nuclear grade; M/V,
volume-corrected mitotic index.
Table III Expression of c-Myc in the cytoplasm as related to
nuclear grade
Expression of c-Myc in the cytoplasm
Variable n Negative Weak Moderate Strong
NG 1 21 7 9 4 1
NG 2 50 3 24 12 11 20.1, 0.002
NG 3 33 4 6 15 8
Table IV Nuclear expression related to T category, tumour
diameter and expression of c-Erb-2
Nuclear expression
No Yes
T category
Ti 3 0 3
T2 48 36 12 6.3, 0.040
T3 40 30 10
T4 12 9 3
Tumour diameter (cm)
<2 1 0 1
2-5 26 15 11 6.7, 0.034
>5 38 31 7
c-Erb-2 expression
Negative 91 69 22
Positive 9 2 7 11.4, 0.0007
Chi-square test.
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Results
Expression ofRb
Rb protein was invariably expressed in normal renal tissue,
whereas in tumours variable expression was detected except
in one tumour, which was completely negative. The mean
(s.e.) fraction of positive nuclei in tumours was 86.8% (2.1%)
(range 0-100%). A normal expression pattern (score 2) was
found in 65/104 (62%) cases and abnormal expression (score
1) in 38/104 (36%) cases. There was marked intra-tumour
variation in the expression of Rb. The fraction of positive
nuclei was negatively correlated to grade and to mitotic index
(Table II). An abnormal expression pattern was positively
correlated with high grade (P = 0.09) and with expression of
c-ErbB-2 (P = 0.0005). Eight out of 61 (13%) tumours that
expressed Rb normally (2) were c-ErbB-2 positive, while only
one tumour with abnormal expression of Rb expressed c-
ErbB-2.
Expression ofc-Myc
Normal renal tissue showed weak cytoplasmic expression of
c-Myc. Twenty-nine out of 104 (28%) tumours showed
nuclear expression of c-Myc. Fourteen out of 104 (13%)
tumours showed no cytoplasmic positivity; in 38/104 (37%)
expression was weak, in 31/104 (30%) moderate and in 20/
104 (19%) strong (Figure ic). Nuclear and cytoplasmic ex-
pression showed significant intra-tumour variation and
usually the invasive areas were intensively positive. Expres-
sion of c-Myc in the cytoplasm was positively correlated to
nuclear grade (Table III) and combined nuclear grade
(P = 0.002).
Nuclear expression of c-Myc was not related to sex, age,
grade, NM classification or expression of p53 (for all
P> 0.2). there was a positive correlation between the expres-
sion of c-ErbB-2 but a negative correlation between tumour
diameter, T category and nuclear expression ofc-Myc (Table
IV). Tumours with a M/V index <7 mm-2 had a higher
fraction of positive nuclei than tumours with a M/V index
>7 mm-2 (4.2% vs 1.0%, t = 2.4, P = 0.019). In survival
analysis cytoplasmic positivity indicated better prognosis in
MO tumours (Figure 2).
Expression ofBcl-2
Bcl-2 was weakly expressed in normal renal tubular cells
(nuclear envelope and cytoplasm). Bcl-2 was expressed
(cytoplasm and nucleus) in 21/104 (20%) of tumours, and
intra-tumour variation was present. Expression of Bcl-2 was
significantly related to tumour size, venous invasion
(P = 0.008) and TNM classification (Table V). Tumours with
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Figure 2 The survival of MO patients categorised according to
cytoplasmic expression of c-Myc. The curves are significantly
separated (X2 = 5.8, P= 0.0157). Curve A: c-Myc (0), n = 8;
Curve B: c-Myc (1, 2, 3), n = 63.
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Table V The mean (s.e.) of Bcl-2-positive nuclei in various
subcategories of renal cell carcinoma
Positive nuclei for Bcl-2
Variable n (s.e.) (%) Statistics
NG 1 21 1.8 (1.0)
NG 2 50 4.6 (1.9) F= 1.8, P=0.17
NG 3 33 0.5 (0.3)
Tl 3 40.6 (20.1)
T2 48 2.6 (1.2)
T3 40 0.5 (0.3) F=25.6, P<0.0001
T4 12 0.6 (0.4)
Tumour diameter (cm)
<2 1 70.0 (-)
2-5 26 3.5 (2.1) F=24.2, P<0.0001
>5 38 2.7 (1.4)
NO 66 4.1 (1.5)
Nl-3 37 0.2 (0.1) t=2.5, P=0.015
MO 76 3.5 (1.3)
Ml 26 0.3 (0.2) t=2.4, P=0.017
a M/V index >7mm2 had a lower fraction of positive
nuclei than the more slowly proliferating ones (0.3% vs
3.9%, t = 2.45, P= 0.017).
Multivariate analysis ofprognosticfactors
Survival was independently related to T category [relative
risk (RR) 2.65, P<0.001], mitotic index (RR = 1.03, P =
0.008) and to combined nuclear grade (RR= 1.19, P =
0.056). Recurrence-free survival of MO tumours was related
to combined nuclear grade (RR = 1.33, P = 0.009), sex
(RR = 0.40, P = 0.018) and T category (RR = 2.05, P=
0.031).
Discussion
The relationship between mutations in the Rb gene and
altered Rb protein expression is not clear-cut since immuno-
histochemically detectable Rb protein may be present even in
cases with mutated Rb gene (Ishikawa et al., 1991; Geradts et
al., 1994). Usually deletions result in total loss of Rb protein
expression while point mutations may result in lowered ex-
pression intensity of the Rb protein (Geradts et al., 1994).
Altered expression of Rb protein was found in 36% ofcases,
which is close to the previously reported figures in other
neoplasms (Logethesis et al., 1992). Previous reports also
suggest a significant relationship between altered Rb expres-
sion, grade and stage in bladder cancer (Cordon-Cardo et al.,
1992; Xu et al., 1993), whereas in this study only grade and
mitotic index were related to expression of Rb. Also, oppo-
site results exist since, according to one recent study, abnor-
mal Rb protein expression is not related to cell proliferation
as measured by proliferating cell nuclear antigen immuno-
labelling (Logethesis et al., 1992). Expression of Rb has been
related to prognosis in some neoplasms (Logathesis et al.,
1992; Cordon-Cardo et al., 1992), while in this analysis
reduced expression of Rb was without prognostic significance
and the prognostic results in breast cancer are similar (Sawan
et at., 1992).
Myc proteins are normally bound to nuclear matrix pro-
teins (Waitz and Loidl, 1991), and analyses based on frozen
tissue sections have demonstrated Myc proteins usually in the
cell nucleus (Kotake et al., 1990; Melhem et al., 1992).
Analyses based on paraffin-embedded tissues have found
Myc positivity in the cytoplasm and in the nucleus (Kotake
et al., 1990; Melhem et al., 1992). This altered cellular dis-
tribution is probably related to dislocation of Myc proteins
related to fixation and processing of the tissue sections, or
they may be less tightly associated with nucleus in malignant
cells.
Amplification or overexpression of c-myc has been pre-
viously related to cell proliferation in human neoplasms
(Munzel et al., 1991; Melhem et al., 1992; Yamaguchi et al.,
1992) albeit the results are variable. In this study cytoplasmic
expression of c-myc was independent of mitotic index while
nuclear expression was related to low proliferation rate.
These results suggest that the relationship between cell pro-
liferation and expression of c-myc is not clear-cut and other
regulatory mechanisms are probably involved. The present
results confirm previous results in that poor histological
differentiation and expression of c-myc are interrelated
(Kotake et al., 1990; Yamaguchi et al., 1992; Lanigan et al.,
1993). Stage of disease and expression of Myc were not
interrelated, which is at variance with previous results in
renal adenocarcinomas (Lanigan et al., 1993).
The prognostic significance of the overexpression or
amplification ofc-myc is disputable in neoplasms (Erisman et
al., 1988; Berns et al., 1992). Our survival analysis suggests
that overexpression of c-myc is related to favourable out-
come. This is probably related to small tumour size to which
overexpression of c-myc was associated. In multivariate ana-
lysis expression of c-myc had no independent prognostic
value which is in agreement with the recent results reported
by Lanigan et al. (1993).
Ultrastructural studies have shown that Bcl-2 immunore-
activity is localised to mitochondrial outer circumference, to
nuclear envelope and to a lesser degree to cell membranes
(Nguyen et al., 1993; de Jong et al., 1994), which is in accord
with the current results. The bct-2 gene product regulates
programmed cell death, and a number of studies suggest that
Bcl-2 is involved in the selection and maintenance of long-
living cells and rescuing them from apoptotic cell death
(Hanada et al., 1993). Bcl-2 protein was weakly expressed in
normal renal tissue and commonly also in well-differentiated
small tumours, while the expression was reduced in tumours
that exhibited features related to high malignancy. These
results are in full agreement with the results ofDoglioni et al.
(1994) in breast cancer. However, the expression ofBcl-2 was
not related to prognosis.
In summing up the results of this analysis, we suggest that
expression of Rb, c-Myc and Bcl-2 proteins is related to cell
proliferation and differentiation of tumours in renal
adenocarcinoma. Expression of these proteins may therefore
have a role in determining tumour behaviour, but further
work is clearly required to elucidate this.
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